2021 ICD-10-CM Code C7A.098
Malignant carcinoid tumors of other sites
Valid for Submission
C7A.098 is a billable diagnosis code used to specify a medical diagnosis of malignant carcinoid tumors of other sites. The code C7A.098 is valid during the fiscal year 2021 from October 01, 2020 through September 30, 2021 for the submission of HIPAA-covered transactions.
The ICD-10-CM code C7A.098 might also be used to specify conditions or terms like carcinoid tumor of pancreas, malignant carcinoid tumor of pancreas, malignant tumor of endocrine pancreas, primary malignant neoplasm of islets of langerhans or primary malignant neuroendocrine neoplasm of pancreas.
| ICD-10: | C7A.098 |
| Short Description: | Malignant carcinoid tumors of other sites |
| Long Description: | Malignant carcinoid tumors of other sites |
Code Classification
Index to Diseases and Injuries
The Index to Diseases and Injuries is an alphabetical listing of medical terms, with each term mapped to one or more ICD-10 code(s). The following references for the code C7A.098 are found in the index:
Approximate Synonyms
The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:
- Carcinoid tumor of pancreas
- Malignant carcinoid tumor of pancreas
- Malignant tumor of endocrine pancreas
- Primary malignant neoplasm of islets of Langerhans
- Primary malignant neuroendocrine neoplasm of pancreas
Diagnostic Related Groups - MS-DRG Mapping
The ICD-10 code C7A.098 is grouped in the following groups for version MS-DRG V38.0 What are Diagnostic Related Groups?
The Diagnostic Related Groups (DRGs) are a patient classification scheme which provides a means of relating the type of patients a hospital treats. The DRGs divides all possible principal diagnoses into mutually exclusive principal diagnosis areas referred to as Major Diagnostic Categories (MDC). applicable from 10/01/2020 through 09/30/2021.
- 826 - MYELOPROLIFERATIVE DISORDERS OR POORLY DIFFERENTIATED NEOPLASMS WITH MAJOR O.R. PROCEDURES WITH MCC - Relative Weight: 5.0368
- 827 - MYELOPROLIFERATIVE DISORDERS OR POORLY DIFFERENTIATED NEOPLASMS WITH MAJOR O.R. PROCEDURES WITH CC - Relative Weight: 2.4976
- 828 - MYELOPROLIFERATIVE DISORDERS OR POORLY DIFFERENTIATED NEOPLASMS WITH MAJOR O.R. PROCEDURES WITHOUT CC/MCC - Relative Weight: 1.6777
Convert C7A.098 to ICD-9 Code
- 209.29 - Malig carcinoid oth site
Information for Patients
Carcinoid Tumors
Carcinoid tumors are rare, slow-growing cancers. They usually start in the lining of the digestive tract or in the lungs. They grow slowly and don't produce symptoms in the early stages. As a result, the average age of people diagnosed with digestive or lung carcinoids is about 60.
In later stages the tumors sometimes produce hormones that can cause carcinoid syndrome. The syndrome causes flushing of the face and upper chest, diarrhea, and trouble breathing.
Surgery is the main treatment for carcinoid tumors. If they haven't spread to other parts of the body, surgery can cure the cancer.
- 5-HIAA (Medical Encyclopedia)
- Carcinoid syndrome (Medical Encyclopedia)
- Serum serotonin level (Medical Encyclopedia)
[Learn More in MedlinePlus]
Code History
- FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
- FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
- FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
- FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
- FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
- FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016 (First year ICD-10-CM implemented into the HIPAA code set)